|
|
Vaccine Detail
|
IL-2, Peptide, and GM-CSF-in-adjuvant Melanoma Vaccine |
| Vaccine Information |
- Vaccine Name: IL-2, Peptide, and GM-CSF-in-adjuvant Melanoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: melanoma and tetanus toxoid peptide (NCT00928902)
- Immunization Route: subcutaneously and intradermally
- Description: This vaccine compromises of melanoma peptides plus GM-CSF-in-adjuvant. It is combined with low-dose IL-2 therapy, which could significantly enhance the immunologic efficacy. (NCT00928902)
|
| Host Response |
|
|
| References |
NCT00928902: Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma (MEL36) [https://clinicaltrials.gov/study/NCT00928902]
|
|
